Paper Title
FIVE MEMBERED RING HYTROCYCLIC COMPOUNDS AS ANTI-CANCER DRUGAbstract
The majority of heterocycle compounds and typically common heterocycle fragments present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility and unique physicochemical properties, have poised them as true cornerstones of medicinal chemistry. Apart from the already marketed drugs, there are many other being investigated for their promising activity against several malignancies. In particular, anticancer research has been capitalizing on the intrinsic versatility and dynamic core scaffold of these compounds. Nevertheless, as for any other promising anticancer drugs, heterocyclic compounds do not come without shortcomings. In this review, we provide for a concise overview of heterocyclic active compounds and families and their main applications in medicine. We shall focus on those suitable for cancer therapy while simultaneously addressing main biochemical modes of action, biological targets, structure-activity relationships as well as intrinsic limitation issues in the use of these compounds. Finally, considering the advent of nanotechnology for effective selective targeting of drugs, we shall discuss fundamental aspects and considerations on nanovectorizatiom of such compounds that may improve pharmacokinetic/pharmacodynamic properties of heterocycles. N-heterocyclic compounds are a natural and rich source of pharmacologically active molecules displaying anti-cancer properties through various antiproliferative mechanisms. Some of these N-heterocyclic compounds are already being utilized or evaluated in clinical settings for cancer treatment, highlighting their potential significance in discovering new anti cancer agents. This study aims to gather information from articles published between 2019 and 2021 on the recent advancements in N-heterocyclic derivatives such as indazole, triazolopyrimidine, pyrazolopyrimidine, quinoxaline, benzimidazole, benzodiazepine, indole, and quinoline as promising anticancer agents, including their structure-activity relationships and mechanisms of action.
KEYWORDS : cancer therapy, heterocyclic compounds, oxygen and nitrogen-based heterocycles, drug delivery, nanomedicine, eterocycles, five-membered heterocycles, antibiotics, antibacterials, nitrogen heterocycles, oxygen heterocycles, sulfur heterocycles, biological activity, drug design, drug discovery.